$CYCC
Cyclacel Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023003163 Filed on March 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.645M $2.143M $7.382M
YoY Change 2.49% 10.41% -1.06%
% of Gross Profit
Research & Development $5.674M $6.702M $20.27M
YoY Change 14.53% 45.92% 30.99%
% of Gross Profit
Depreciation & Amortization $8.000K $8.000K $32.00K
YoY Change -11.11% 14.29% -25.58%
% of Gross Profit
Operating Expenses $7.319M $8.845M $27.66M
YoY Change 11.59% 35.37% 20.57%
Operating Profit -$7.319M -$27.66M
YoY Change 11.59% 20.57%
Interest Expense $29.00K -$159.0K $443.0K
YoY Change -12.12% -469.77% 638.33%
% of Operating Profit
Other Income/Expense, Net $195.0K $4.000K $1.741M
YoY Change -85.15% 753.43%
Pretax Income -$7.124M -$9.000M -$25.92M
YoY Change 35.8% 38.65% 13.99%
Income Tax -$1.320M -$1.581M -$4.717M
% Of Pretax Income
Net Earnings -$5.804M -$7.469M -$21.20M
YoY Change 41.29% 41.08% 12.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.47 -$1.90
Diluted Earnings Per Share -$0.47 -$0.60 -$1.90
COMMON SHARES
Basic Shares Outstanding 12.54M 12.54M 11.26M
Diluted Shares Outstanding 12.54M 11.26M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.44M $18.35M $18.35M
YoY Change -61.42% -49.82% -49.82%
Cash & Equivalents $11.40M $18.35M $18.35M
Short-Term Investments
Other Short-Term Assets $595.0K $426.0K $1.402M
YoY Change -61.34% 439.24% 113.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.97M $24.41M $24.41M
YoY Change -48.13% -40.38% -40.38%
LONG-TERM ASSETS
Property, Plant & Equipment $31.00K $32.00K $174.0K
YoY Change -45.61% -50.0% 85.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.916M $2.916M $2.916M
YoY Change -2.15% 88.01% 88.01%
Total Long-Term Assets $3.086M $3.090M $3.090M
YoY Change 1.11% 87.84% 87.84%
TOTAL ASSETS
Total Short-Term Assets $18.97M $24.41M $24.41M
Total Long-Term Assets $3.086M $3.090M $3.090M
Total Assets $22.06M $27.50M $27.50M
YoY Change -44.33% -35.42% -35.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.509M $2.561M $2.561M
YoY Change -11.96% 20.97% 20.97%
Accrued Expenses $4.829M $4.831M $3.944M
YoY Change 43.98% 52.06% 55.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.338M $7.392M $7.392M
YoY Change 18.28% 39.63% 39.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.00K $106.0K $106.0K
YoY Change 433.33% 253.33% 253.33%
Total Long-Term Liabilities $80.00K $106.0K $106.0K
YoY Change 433.33% 253.33% 253.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.338M $7.392M $7.392M
Total Long-Term Liabilities $80.00K $106.0K $106.0K
Total Liabilities $7.418M $7.498M $7.498M
YoY Change 19.28% 40.83% 40.83%
SHAREHOLDERS EQUITY
Retained Earnings -$412.0M -$406.2M
YoY Change 5.88% 5.52%
Common Stock $9.000K $9.000K
YoY Change -10.0% -10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.15M $15.51M $20.00M
YoY Change
Total Liabilities & Shareholders Equity $22.06M $27.50M $27.50M
YoY Change -44.33% -35.42% -35.42%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$5.804M -$7.469M -$21.20M
YoY Change 41.29% 41.08% 12.24%
Depreciation, Depletion And Amortization $8.000K $8.000K $32.00K
YoY Change -11.11% 14.29% -25.58%
Cash From Operating Activities -$6.861M -$5.169M -$20.83M
YoY Change 1.27% 13.63% 12.34%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $0.00 $7.000K
YoY Change 50.0% -100.0% -74.07%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.000K $0.00 -$7.000K
YoY Change 50.0% -100.0% -74.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.00K 42.00K 2.998M
YoY Change 0.0% -95.26% -86.21%
NET CHANGE
Cash From Operating Activities -6.861M -5.169M -20.83M
Cash From Investing Activities -6.000K 0.000 -7.000K
Cash From Financing Activities -50.00K 42.00K 2.998M
Net Change In Cash -6.910M -5.127M -18.21M
YoY Change -0.14% 39.93% -677.67%
FREE CASH FLOW
Cash From Operating Activities -$6.861M -$5.169M -$20.83M
Capital Expenditures $6.000K $0.00 $7.000K
Free Cash Flow -$6.867M -$5.169M -$20.83M
YoY Change 1.3% 13.68% 12.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2916000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1551000
CY2022 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2021 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2022 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8926173
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8926173
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2022 dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53300000
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3117100
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
00-50626
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2022 dei City Area Code
CityAreaCode
908
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12539189
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9993135
CY2022 dei Local Phone Number
LocalPhoneNumber
517-7330
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
11477812
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12539189
CY2022 dei Auditor Firm
AuditorFirmId
49
CY2022 dei Auditor Name
AuditorName
RSM US LLP
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36559000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24411000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
40942000
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001130166
CY2022Q4 us-gaap Assets
Assets
27501000
CY2021Q4 us-gaap Assets
Assets
42587000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2117000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7392000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5294000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30000
CY2022Q4 us-gaap Liabilities
Liabilities
7498000
CY2021Q4 us-gaap Liabilities
Liabilities
5324000
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3117100
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12539189
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9993135
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422973000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422960000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1316000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-748000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406157000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384959000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27501000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42587000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20274000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15477000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7382000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7461000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
27656000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
22938000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-27656000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-22938000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
233000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
44000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
210000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1298000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
144000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1741000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
204000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21399000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19088000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11255677
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11255677
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8926173
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8926173
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20598000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2123000
CY2022 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-21166000
CY2021 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2125000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21766000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18889000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
33259000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13502000
CY2021 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
3870000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4565000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1157000
CY2021 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2021 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2125000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2123000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
3201000
CY2022 cycc Increase In Carrying Amount Of Redeemable Common Stock
IncreaseInCarryingAmountOfRedeemableCommonStock
4494000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1506000
CY2022 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-21166000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20598000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2022 us-gaap Depreciation
Depreciation
32000
CY2021 us-gaap Depreciation
Depreciation
43000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1506000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1157000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
40000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
172000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3784000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3931000
CY2022 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2577000
CY2021 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2906000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20827000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18540000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2022 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
3199000
CY2021 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
17371000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
4567000
CY2022 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2021 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2998000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21737000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-378000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-17000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18214000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3153000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33406000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2022 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
211000
CY2021 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
17000
CY2022 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3312000
CY2021 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1358000
CY2022 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2021 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18900000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21200000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18300000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company’s consolidated financial statements.</p>
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
17800000
CY2022Q4 cycc Cash Financial Services Compensation Scheme Insured Amount
CashFinancialServicesCompensationSchemeInsuredAmount
85000
CY2022Q4 cycc Cash Exceeding Balance Insured By Financial Services Compensation Scheme
CashExceedingBalanceInsuredByFinancialServicesCompensationScheme
200000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-3487000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-2807000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
2
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
328000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
6169000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
4967000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4719000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3849000
CY2021 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2022 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2021Q4 cycc License Agreement Potential Future Milestone Payments
LicenseAgreementPotentialFutureMilestonePayments
0
CY2022Q4 cycc License Agreement Potential Future Milestone Payments
LicenseAgreementPotentialFutureMilestonePayments
0
CY2022Q4 us-gaap Cash
Cash
13798000
CY2021Q4 us-gaap Cash
Cash
32082000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
4547000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
4477000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36559000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
105000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2310000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15296000
CY2022 cycc Income Tax Reconciliation Foreign Income Tax Rate Differential And Repatriation Of Foreign Earnings
IncomeTaxReconciliationForeignIncomeTaxRateDifferentialAndRepatriationOfForeignEarnings
-20000
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
4664000
CY2021Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
3727000
CY2022Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
976000
CY2021Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
577000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2900000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
415000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
425000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
383000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
361000
CY2022Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3611000
CY2021Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2310000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
233000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
887000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
634000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
680000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
495000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
65000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
166000
CY2021 cycc Income Tax Reconciliation Foreign Income Tax Rate Differential And Repatriation Of Foreign Earnings
IncomeTaxReconciliationForeignIncomeTaxRateDifferentialAndRepatriationOfForeignEarnings
-177000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-2000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-12831000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1506000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1157000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
552153
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
522337
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2000000.0
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6600
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2022 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1981000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1622000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-23934000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21112000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-4719000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-3849000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-4717000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-3847000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3800000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
4700000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5442000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4774000
CY2022 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
369000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53092000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56629000
CY2022Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
61000
CY2021Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
34000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
153000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
67000
CY2022Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-40000
CY2021Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-32000
CY2022Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
40000
CY2021Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
32000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53306000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
56730000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53306000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56730000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2022 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2021 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21399000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19088000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11255677
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11255677
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6178036
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5548138
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2022Q4 us-gaap Assets
Assets
27501000
CY2021Q4 us-gaap Assets
Assets
42587000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2022Q4 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2022-12-06
CY2022Q4 us-gaap Preferred Stock Dividends Per Share Declared
PreferredStockDividendsPerShareDeclared
0.15

Files In Submission

Name View Source Status
0001558370-23-003163-index-headers.html Edgar Link pending
0001558370-23-003163-index.html Edgar Link pending
0001558370-23-003163.txt Edgar Link pending
0001558370-23-003163-xbrl.zip Edgar Link pending
cycc-20221231.xsd Edgar Link pending
cycc-20221231x10k.htm Edgar Link pending
cycc-20221231xex10d16.htm Edgar Link pending
cycc-20221231xex23d1.htm Edgar Link pending
cycc-20221231xex31d1.htm Edgar Link pending
cycc-20221231xex31d2.htm Edgar Link pending
cycc-20221231xex32d1.htm Edgar Link pending
cycc-20221231xex32d2.htm Edgar Link pending
cycc-20221231xex4d10.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
cycc-20221231_pre.xml Edgar Link unprocessable
cycc-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycc-20221231x10k_htm.xml Edgar Link completed
cycc-20221231_cal.xml Edgar Link unprocessable
cycc-20221231_def.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending